BioMed Ventures: Funding, Team & Investors | Startup Intros

Loading organizations...

BioMed Ventures: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Sep 1, 2021	Fauna Bio	$9.0M Seed	Lifeforce Capital	Bija Ventures, Arcadia Science, Boom Capital, Pacific 8 Ventures, True Ventures, Vibe Capital
May 1, 2020	Amplyx Pharmaceuticals	$53.0M Series C	Sofinnova Ventures	Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, 3x5 Partners, Adage Capital Management, Arix Bioscience, Lundbeckfond Ventures, Pappas Capital, Pfizer, RiverVest Venture Partners
Jul 1, 2018	Compass Therapeutics	$49.0M Series A	Carl Gordon	Atlas Venture, F-Prime Capital Partners, Alexandria Venture Investments, Biomatics Capital, Borealis Ventures, Cowen Healthcare Investments, F-Prime Capital, Thiel Capital, Ulysses Diversified Holdings
Jan 2, 2018	AEGEA Medical	$40.0M Other Equity	Sam Chawla	Alloy Ventures, Delphi Ventures, Medtronic, Solas BioVentures
Jul 1, 2017	Amplyx Pharmaceuticals	$67.0M Series C	Anand Mehra	Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, Mark Chin, Johan Kördel, Pappas Capital, RiverVest Venture Partners
Jul 1, 2017	Effector Therapeutics	$39.0M Series C	—	Sofinnova Investments, AbbVie Ventures, Abingworth, Alexandria Venture Investments, Astellas Venture Management, Novartis, Sectoral Asset Management, SR One, The Column Group, U.S. Venture Partners
Jul 1, 2017	NeuroVia	$14.0M Series A	Sanofi Ventures, Novartis	Enso Ventures
Nov 1, 2015	Amplyx Pharmaceuticals	$41.0M Series B	Niall O'Donnell	Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest
Aug 1, 2015	Syndax Pharmaceuticals	$80.0M Series C	Delos, Fidelity Management & Research Company	aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital, Arrowpoint Partners, Cormorant Asset Management, EcoR1 Capital, Forward Ventures, Greenwood Capital, Jennison Associates, MPM Capital, OrbiMed, RusnanoMedInvest, Tavistock Group
Jul 1, 2015	AnaptysBio	$40.0M Series D	—	Frazier Healthcare Partners, Versant Ventures, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Longwood Capital Partners, Novo Holdings
May 4, 2015	AEGEA Medical	$36.0M Series C	—	Alloy Ventures, Covidien, Delphi Ventures, Solas BioVentures
Apr 1, 2015	Edge Therapeutics	$56.0M Series C	Anders Hove	1955 Capital, Aberdare Ventures, Acorn Bioventures, Founders Fund, Highbury Group, Lightspeed Venture Partners, OrbiMed, Sequoia Capital, Sofinnova Investments, Ted Driscoll, Franklin Templeton, Janus Henderson Investors, New Leaf Venture Partners
Feb 1, 2015	Laguna Pharmaceuticals	$30.0M Series B	Frazier Healthcare Partners, Versant Ventures	Bessemer Venture Partners, Third Rock Ventures, Sante Ventures
Sep 1, 2014	TRACON Pharmaceuticals	$27.0M Series B	—	New Enterprise Associates, Arcus Ventures, BHP Ventures, Bruce D. Steel, Brookline Investments, Jafco Ventures, Nextech Invest
Jan 8, 2014	Auspex Pharmaceuticals	$35.0M Debt / Series E	Jonathan Leff	CMEA Capital, Costa Verde Capital, Oxford Finance, Panorama Capital, Thomas, McNerney & Partners
Dec 1, 2012	NanoString Technologies	$15.0M Series E	—	GE Ventures, Henri Termeer, AllianceBernstein, Clarus Ventures, Draper Fisher Jurvetson, GE, Morgan Stanley, OVP Venture Partners
Nov 7, 2011	NanoString Technologies	$20.0M Series D	—	Henri Termeer, Clarus Ventures, Draper Fisher Jurvetson, Pascale Witz, OVP Venture Partners